Gilead Sciences (GILD)
(Real Time Quote from BATS)
$83.73 USD
-0.21 (-0.25%)
Updated Sep 23, 2024 11:38 AM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Price, Consensus and EPS Surprise
GILD 83.73 -0.21(-0.25%)
Will GILD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GILD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GILD
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
GILD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
Gilead Stock Rises as HIV Prevention Injection Meets Study Goals
Other News for GILD
Dividend Champion, Contender, And Challenger Highlights: Week Of September 22
Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success
First Week of GILD May 2025 Options Trading
Wells Fargo’s ‘Value Equity List’ – Stocks with potential that trade at a discount
Working to Build Next-Generation Cancer Therapies